Medical Search Australia Trusted by 250,000+ buyers

NEW piCO Baby Smokerlyzer

Supplier: Niche Medical By: Craig Abud
07 April, 2015

NEW piCO Baby Smokerlyzer - Breath Carbon Monoxide Monitoring for Maternity

The piCO Baby Smokerlyzer has been specifically designed for use in pregnancy with results shown instantly in exact ppm, %COHb (Carboxyhaemoglobin) and %FCOHb (Foetal Carboxyhaemoglobin) making recording and interpreting Patients' results quick and easy.

Oxygen is required by a foetus for healthy growth, but the supply of vital oxygen is reduced when the mother smokes. This increases the risk of low birthweight, birth defects and even Sudden Infant Death Syndrome.

A clinical study established a direct link between an expectant mother's breath CO level and the amount of COHb in their unborn baby's blood.

Study: Expired air carbon monoxide concentration in mothers and their spouses above 5ppm is associated with decreased foetal growth

Authors: Conchita Gomez, Midwife, Ivan Berlin, M.D., Ph.D., Pierre Marquis, M.D., and Michel Delcroix, M.D. Preventative Medicine 40 (2005) 1-15

Background: Smoking during pregnancy is associated with reduced birthweight; this relationship can be reversed by smoking cessation. Some but not all previous studies have shown that smoking reduction (measured as cigarettes per day or urinary cotinine) may also improve birthweight. The relationship between maternal and spouses' expired air carbon monoxide (CO) concentrations (EACO) on foetal growth has not yet been evaluated.

Methods: Eight hundred fifty-six smoking and non-smoking pregnant women were followed during their pregnancy. Their EACO was determined in the first trimester and during delivery. The spouses' EACO were also measured at delivery. The main outcome measure was the infants' birthweight.

Secondary measures included head circumference, Apgar score, and heart rate at delivery. Cord blood foetal carboxyhaemoglobin (FCOHb) served as internal control.

Results: Birthweight dose-dependently and significantly decreased with increasing levels of maternal (0 - 5: 3546 +- 25: 6-10: 3048 +- 57; 11 - 20: 2858 +- 54; > 20 ppm: 2739 +- 34g, P , 0.0001) or spouses' EACO (0-5: 3546 +- 25; 6-10: 3484 +- 51; 11 - 20: 3309 +- 47; > 20 ppm: 3190 +- 57g, P < 0.0001).

Even the birthweight of newborns whose mother had EACO between 6 and 10 ppm was significantly lower than the birthweight of newborns whose mother had an EACO between 0 and 5 ppm. Spuoses' EACO of delivering women with EACO of 0 - 5 ppm showed similar effect. Head circumference, Apgar score, and normal term gestational age decreased also significantly with increasing maternal or spouses' EACO.

Conclusions: Both maternal and spouses' EACO measured during delivery, a proxy of EACO during pregnancy, were dose-dependently and inversely associated with foetal growth. Even low maternal (6 to 10 ppm) or spouses' (11 to 20 ppm) EACO may be associated with significantly lower birthweight.